Can traditional disease-Modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis?

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.78, 2013, Pages

  Lubrano, Ennio ^a   Soriano, Enrique ^b   FitzGerald, Oliver ^c  

^a UNIVERSITY OF MOLISE   (Italy)

^b Instituto Universitario del Hospital Italianode Buenos Aires and   (Argentina)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Arthritis; Psoriatic; Traditional DMARDs; Treatment withdrawal

Indexed keywords

ANTIMALARIAL AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ABSENCE OF SIDE EFFECTS; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CYTOKINE PRODUCTION; DACTYLITIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE REGISTRY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECHOGRAPHY; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LONGITUDINAL STUDY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT DECISION MAKING; POLYARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PATIENT SELECTION; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885774151     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. HAROON M, FitzGERALD O: Pathogenetic overview of psoriatic disease. J Rheumatol 2012; 89 (Suppl.): 7-10.
2. CURRAN SA, FitzGERALD OM, COSTELLO PJ et al.: Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 2004; 1172: 1935-44.
3. McHUGH NJ, BALACHRISHNAN C, JONES SM: Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003; 42: 778-83.
4. KANE D, STAFFORD L, BRESNIHAN B, FitzGERALD O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003; 42: 1460-8.
5. SMOLEN JS, BRAUN J, DOUGADOS M et al.: Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2013 Jun 8 [Epub ahead of print].
6. PIPITONE N, KINGSLEY GH, MANZO A, SCOTT DL, PITZALIS C: Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 1138-48.
7. HELLIWELL PS, TAYLOR WJ, GROUP CS: Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions. J Rheumatol 2008; 35: 472-6.
8. SORIANO ER: The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis. J Rheumatol Suppl 2012; 89: 67-70.
9. SALVARANI C, PIPITONE N, MARCHESONI A et al.: Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 2011; 29 (Suppl. 66): S28-41.
10. LUBRANO E, SCARPA R: Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs. Reumatismo 2012; 64: 107-12.
11. KAVANAUGH AF, RITCHLIN CT; GRAPPA TREATMENT GUIDELINE COMMITTEE.: Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006; 33: 1417-21.
12. RICCI M, DE MARCO G, DESIATI F et al.: [Long-term survival of methotrexate in psoriatic arthritis]. Reumatismo 2009; 61: 125-31.
13. FAGERLI KM, LIE E, van der HEIJDE D et al.: The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2013 Jan 3 [Epub ahead of print].
14. LIE E, van der HEIJDE D, UHLIG T et al.: Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 671-6.
15. KINGSLEY GH, KOWALCZYK A, TAYLOR H et al.: A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012; 51: 1368-77.
16. COATES LC, NAVARRO-COY N, BROWN SR et al.: The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 2013; 14: 101.
17. CLEGG DO, REDA DJ, ABDELLATIF M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42: 2325-9.
18. SPADARO A, RICCIERI V, SILI-SCAVALLI A, SENSI F, TACCARI E, ZOPPINI A: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995; 13: 589-93.
19. SALVARANI C, MACCHIONI P, OLIVIERI I et al.: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28: 2274-82.
20. BEHRENS F, FINKENWIRTH C, PAVELKA K et al.: Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res 2013; 65: 464-70.
21. GOSSEC L, SMOLEN JS, GAUJOUX-VIALA C et al.: European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12.
22. GLADMAN DD, HING EN, SCHENTAG CT, COOK RJ: Remission in psoriatic arthritis. J Rheumatol 2001; 28: 1045-8.
23. GLADMAN DD, CHANDRAN V, THAVANESWARAN A, ZUMMER M: Psoriatic arthritis in Canadian clinical practice: the PsA assessment in rheumatology. J Rheumatol 2012; 39: 1850-3.
24. CANTINI F, NICCOLI L, NANNINI C et al.: Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs. J Rheumatol Suppl 2009; 83: 78-80.
25. CANTINI F, NICCOLI L, NANNINI C et al.: Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 2008; 47: 872-6.
26. THEANDER E, HUSMARK T, ALENIUS GM et al.: Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis 2013 Jan 25 [Epub ahead of print].
27. LINDQVIST UR, ALENIUS GM, HUSMARK T et al.: The Swedish early psoriatic arthritis register-- 2-year follow-up: a comparison with early rheumatoid arthritis. J Rheumatol 2008; 35: 668-73.
28. KAVANAUGH A, FRANSEN J: Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006; 24 (Suppl. 43): S83-087.
29. CAPERON A, HELLIWELL PS: Remission in psoriatic arthritis. J Rheumatol Suppl 2012; 89: 19-21.
30. COATES LC, FRANSEN J, HELLIWELL PS: Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69: 48-53.
31. DEJACO CEA: Disparity Between Sonographic and Clinical Criteria of Remission in Psoriasis Arthritis. Arthritis Rheum 2012; 64 (Suppl.): S48.
32. FitzGERALD O, HELLIWELL P, MEASE P et al.: Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis 2012; 71: 358-62.
33. MUMTAZ A, GALLAGHER P, KIRBY B et al.: Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011; 70: 272-7.